- Fluor (NYSE:FLR) says it was awarded a contract to design and build Novo Nordisk's (NVO) new $2B diabetes Active Pharmaceutical Ingredient manufacturing facility in North Carolina.
- FLR has been providing basic design services since NVO announced plans for the new facility in August 2015 and now will be executing the full scope of work.
- FLR +1.1% AH.
Fluor to design, build Novo Nordisk $2B diabetes API manufacturing plant
Recommended For You
About FLR Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| FLR | - | - |
| Fluor Corporation | ||